Dhampur Bio (DBOL)

FairStock Score: 29/100 — RISKY

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Trades at 0.80 P/B, a 20% discount to book value of ₹149.19
• Moderate debt-to-equity of 0.58
• Piotroski F-score of 7/9 indicates sound financial health
• Promoter holding of 50.65% aligns management with shareholders
• Latest quarter shows net profit of ₹17 Cr on sales of ₹486 Cr, indicating recent operational recovery

Concerns

• ROE of 1.89% and ROCE of 3.97% are far too low to create shareholder value
• P/E of 28.72 is expensive given the cyclical and commoditized sugar business
• Profit growth of 431% is off a low base and likely unsustainable
• FairStock Score of 28/100 flags high overall risk

AI Analysis

Let me look at Dhampur Bio through a lens I've sharpen over decades. A sugar company in India, selling at ₹118.85 against a book value of ₹149.19 - that's a P/B of 0.80. On the surface, you're buying one rupee of assets for eighty paise. But cheapness is only meaningful if the assets earn a decent return. Here, ROE is a meagre 1.89% and ROCE stands at 3.97%. That tells me this is a low-return business chewing up capital, not compounding it. The sugar industry is inherently cyclical and commoditized; there's little moat. Government policies, cane prices, and global sugar prices dictate fate more than management skill. Sales growth of 4.74% is pedestrian, and while profit growth of 431% sounds extraordinary, it's off a tiny base. The latest quarter shows ₹17 Cr net profit on ₹486 Cr sales - a margin under 3.5%, hardly a franchise. Debt-to-equity at 0.58 is acceptable, and a Piotroski score of 7/9 suggests the balance sheet isn't deteriorating. Promoter holding of 50.65% is encouraging, signaling skin in the game. But with a P/E of 28.72, the market is paying a full price for a volatile earnings stream. Dividend yield of 1.22% offers little comfort. This looks like a cyclical recovery, not a compounding machine. I'd only consider it at a deeper margin of safety, or if you believe sugar prices have turned for a multi-year upcycle. Even then, the low ROE caps intrinsic value. In Graham's words, it's a cigar butt - one puff left, maybe. Not a business I'd want to own forever.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer